KR880007528A - [3s(z)]-2[[[1-(2-아미노-4-티아졸릴)-2-[[2,2-디메틸-4-옥소-1-(술포옥시)-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]아세트산의 결정질 염류 - Google Patents

[3s(z)]-2[[[1-(2-아미노-4-티아졸릴)-2-[[2,2-디메틸-4-옥소-1-(술포옥시)-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]아세트산의 결정질 염류 Download PDF

Info

Publication number
KR880007528A
KR880007528A KR870014447A KR870014447A KR880007528A KR 880007528 A KR880007528 A KR 880007528A KR 870014447 A KR870014447 A KR 870014447A KR 870014447 A KR870014447 A KR 870014447A KR 880007528 A KR880007528 A KR 880007528A
Authority
KR
South Korea
Prior art keywords
amino
compound
oxoethylidene
sulfooxy
thiazolyl
Prior art date
Application number
KR870014447A
Other languages
English (en)
Other versions
KR960007534B1 (ko
Inventor
로렌스 파커 윌리암
몰톤 코헨 에드워드
헨리 코스터 윌리암
Original Assignee
니콜라스 피.말라테스티닉
이이. 아르. 스퀴부 앤드 산즈 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니콜라스 피.말라테스티닉, 이이. 아르. 스퀴부 앤드 산즈 인코오포레이티드 filed Critical 니콜라스 피.말라테스티닉
Publication of KR880007528A publication Critical patent/KR880007528A/ko
Application granted granted Critical
Publication of KR960007534B1 publication Critical patent/KR960007534B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음.

Description

[3S(Z)]-2[[[1-(2-아미노-4-티아졸릴)-2-[[2,2-디메틸-4-옥소-1-(술포옥시)-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]아세트산의 결정질 염류
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 화합물 [3S(Z)]-2[[[1-(2-아미노-4-티아졸릴)-2-[[2,2-디메틸-4-옥소-1-(술포옥시)-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]아세트산의 이에리트로마이신염 및 이콜린염.
  2. 제1항에 있어서, 결정형 화합물.
  3. 화합물 [3S(Z)]-2[[[1-(2-아미노-4-티아졸릴)-2-[[2,2-디메틸-4-옥소-1-(술포옥시)-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]아세트산의 이에리트로마이신염 또는 이콜린염 유효량을 필요로 하는 포유동물에 투여하는 것으로 되는, 포유 동물의 세균 감염 치료 방법.
  4. 하기 구조식(Ⅰ)로 표시되는 화합물의 유리산(여기에서 M=H)을 용매 존재 하에 에리트로마이신 또는 콜린과 반응시켜서 일반식(Ⅰ) 화합물의 이에리트로 마이신염 또는 이콜린염을 얻는 것으로 되는, M가 에리트로마이신 또는 콜린인 하기 구조식(Ⅰ)을 갖는 화합물의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870014447A 1986-12-19 1987-12-18 [3에스(지)]-2[[[1-(2-아미노-4-티아졸릴)-2-[[2,2-디메틸-4-옥소-1-(술포옥시)-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]아세트산의 결정질 염류 KR960007534B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/944,283 US4751220A (en) 1986-12-19 1986-12-19 Crystalline salts of [3S(Z)]-2[[[1-(2-amino-4-thiazolyl)-2-[[2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl]amino]-2-oxoethylidene]-amino]oxy]acetic acid
US944283 1986-12-19
US944,283 1997-10-06

Publications (2)

Publication Number Publication Date
KR880007528A true KR880007528A (ko) 1988-08-27
KR960007534B1 KR960007534B1 (ko) 1996-06-05

Family

ID=25481130

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870014447A KR960007534B1 (ko) 1986-12-19 1987-12-18 [3에스(지)]-2[[[1-(2-아미노-4-티아졸릴)-2-[[2,2-디메틸-4-옥소-1-(술포옥시)-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]아세트산의 결정질 염류

Country Status (25)

Country Link
US (1) US4751220A (ko)
JP (1) JP2511083B2 (ko)
KR (1) KR960007534B1 (ko)
AU (1) AU600536B2 (ko)
BE (1) BE1000625A3 (ko)
CA (1) CA1296717C (ko)
CH (1) CH674009A5 (ko)
DE (1) DE3743111C2 (ko)
DK (1) DK671487A (ko)
ES (1) ES2007766A6 (ko)
FI (1) FI91757C (ko)
FR (1) FR2610627B1 (ko)
GB (1) GB2199033B (ko)
GR (1) GR871937B (ko)
HU (1) HU197568B (ko)
IE (1) IE61325B1 (ko)
IL (1) IL84521A (ko)
IT (1) IT1233457B (ko)
LU (1) LU87076A1 (ko)
NL (1) NL193639C (ko)
NZ (1) NZ222599A (ko)
PH (1) PH23170A (ko)
PT (1) PT86403B (ko)
SE (1) SE467782B (ko)
ZA (1) ZA879031B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US7041650B2 (en) * 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
AU2002359721A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
CN101724000B (zh) * 2008-10-29 2012-05-30 广东东阳光药业有限公司 一种红霉素的结晶方法
CN113754651B (zh) * 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN115463219A (zh) * 2021-11-09 2022-12-13 中国医学科学院医药生物技术研究所 包含β-内酰胺类化合物的药物组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES376380A1 (es) * 1970-01-30 1972-04-16 Roger Lab Procedimiento de obtencion de un nuevo derivado de eritro- micina.
AU8364875A (en) * 1974-08-21 1977-02-10 Hoffmann La Roche Choline and n-methyl-d-glucamine salts of amoxycillin
US4337197A (en) * 1980-10-31 1982-06-29 E. R. Squibb & Sons, Inc. O-sulfated β-lactam hydroxamic acids and intermediates
US4533660A (en) * 1980-10-31 1985-08-06 E. R. Squibb & Sons, Inc. Antibacterial O-sulfated β-lactam hydroxamic acids
US4638061A (en) * 1985-01-28 1987-01-20 E. R. Squibb & Sons, Inc. [3S(Z)]-2-[[[1-(2-amino-4-thiazolyl)-2-[[2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl]amino]-2-oxoethylidene]-amino]oxy] acetic acid and intermediate

Also Published As

Publication number Publication date
LU87076A1 (fr) 1988-07-14
FI91757C (fi) 1994-08-10
BE1000625A3 (fr) 1989-02-21
FI875159A0 (fi) 1987-11-23
IE61325B1 (en) 1994-11-02
PT86403A (en) 1988-01-01
PT86403B (pt) 1990-11-20
DE3743111A1 (de) 1988-06-30
AU8185787A (en) 1988-06-23
SE467782B (sv) 1992-09-14
HU197568B (en) 1989-04-28
HUT45998A (en) 1988-09-28
FR2610627A1 (fr) 1988-08-12
NL8703047A (nl) 1988-07-18
IT1233457B (it) 1992-04-02
IL84521A0 (en) 1988-04-29
IT8722908A0 (it) 1987-12-07
US4751220A (en) 1988-06-14
NL193639B (nl) 2000-01-03
GB8727048D0 (en) 1987-12-23
AU600536B2 (en) 1990-08-16
FI875159A (fi) 1988-06-20
KR960007534B1 (ko) 1996-06-05
SE8705068L (sv) 1988-06-20
FR2610627B1 (fr) 1989-12-01
JP2511083B2 (ja) 1996-06-26
DK671487A (da) 1988-06-20
FI91757B (fi) 1994-04-29
IE873447L (en) 1988-06-19
GR871937B (en) 1988-04-26
NL193639C (nl) 2000-05-04
PH23170A (en) 1989-05-19
ZA879031B (ko) 1988-05-27
ES2007766A6 (es) 1989-07-01
NZ222599A (en) 1989-09-27
CA1296717C (en) 1992-03-03
GB2199033B (en) 1990-10-24
CH674009A5 (ko) 1990-04-30
SE8705068D0 (sv) 1987-12-18
JPS63165381A (ja) 1988-07-08
DK671487D0 (da) 1987-12-18
IL84521A (en) 1992-02-16
GB2199033A (en) 1988-06-29
DE3743111C2 (de) 1996-04-04

Similar Documents

Publication Publication Date Title
KR890002141A (ko) 무정형 아즈트레오남
KR870010024A (ko) 티오락탐-n-아세트산 유도체, 그의 제조방법 및 용도
KR850001905A (ko) 벤조시클로 알칸 유도체의 제조방법
KR880001282A (ko) 옥사자포스포린 용액 및 이의 제조방법
KR890009962A (ko) 매뉴마이신 유도체, 이의 제조방법 및 용도
KR870007202A (ko) 신규 글리코펩티드계 항생물질
FI841161A (fi) Foerening och komposition foer terapeutisk eller diagnostisk anvaendning jaemte foerfarande foer terapeutisk behandling.
KR830006198A (ko) 시클로헥산 유도체의 제조방법
KR880007528A (ko) [3s(z)]-2[[[1-(2-아미노-4-티아졸릴)-2-[[2,2-디메틸-4-옥소-1-(술포옥시)-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]아세트산의 결정질 염류
KR890012991A (ko) 광학활성을 갖는 4-옥소-1-벤조피란-2-카르복시산 유도체 및 중간체의 제법
KR870002150A (ko) 알킬카르바모일옥시메틸 세펨화합물의 제조방법
KR910021400A (ko) 옥사졸리디논
KR850001766A (ko) 무라밀디펩타이드 활성 에스테르 유도체의 제조방법
KR890003755A (ko) 7- (2- 메틸- 4- 아미노피롤리디닐)나프티리딘 및 퀴놀린 화합물
KR890003725A (ko) 아민유도체 및 이의 염, 이의 제조방법 및 이를 함유하는 궤양치료제
KR890014504A (ko) 4-(2'-시아노 에틸티오)메틸-2-구아니디노티아졸의 제조방법
KR870010062A (ko) 세파로스포린 유도체의 제조방법
KR920002497A (ko) 스테롤 화합물
KR880002536A (ko) 옥시란 슈도올리고삭카라이드, 이의 제조방법 및 이의 용도 및 약제학적 제제
KR850000454A (ko) 세팔로스포린 유도체의 제조방법
KR880001634A (ko) 피로글루타미드 유도체 그 제조방법
KR910000773A (ko) 3-페닐티오시알산 유도체, 시알산 함유 올리고삭카라이드 유도체 및 이들의 제조방법
KR830005151A (ko) 헤테로 시클릭 화합물의 제조 방법 및 이것의 조성물
KR910000712A (ko) 이미다졸 유도체의 제조방법
KR890016032A (ko) 푸란 유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020522

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee